SG11201402343SA - Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate - Google Patents

Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Info

Publication number
SG11201402343SA
SG11201402343SA SG11201402343SA SG11201402343SA SG11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA
Authority
SG
Singapore
Prior art keywords
egfr
tumors
resistant
treatment
cytotoxic agent
Prior art date
Application number
SG11201402343SA
Inventor
Julianto Setiady
Peter U Park
Thomas Chittenden
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG11201402343SA publication Critical patent/SG11201402343SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
SG11201402343SA 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate SG11201402343SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161562157P 2011-11-21 2011-11-21
US201261639452P 2012-04-27 2012-04-27
PCT/US2012/066205 WO2013078271A1 (en) 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Publications (1)

Publication Number Publication Date
SG11201402343SA true SG11201402343SA (en) 2014-06-27

Family

ID=48470279

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402343SA SG11201402343SA (en) 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Country Status (16)

Country Link
US (1) US9233171B2 (en)
EP (1) EP2794010A4 (en)
JP (1) JP2014533954A (en)
KR (1) KR20140105765A (en)
CN (1) CN104066481A (en)
AU (1) AU2012340686A1 (en)
BR (1) BR112014012155A2 (en)
CA (1) CA2856411A1 (en)
CL (1) CL2014001282A1 (en)
HK (1) HK1201772A1 (en)
IL (1) IL232666A0 (en)
MX (1) MX2014006087A (en)
PH (1) PH12014501119A1 (en)
RU (1) RU2014121820A (en)
SG (1) SG11201402343SA (en)
WO (1) WO2013078271A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013010569A2 (en) 2010-10-29 2017-07-04 Immunogen Inc non-antagonistic and immunoconjugated egfr binding molecules thereof
BR112013010544A2 (en) 2010-10-29 2016-08-02 Immunogen Inc egfr and immunoconjugate binding molecules thereof
ES2860748T3 (en) 2011-01-24 2021-10-05 Gilead Sciences Inc Selective Antibodies for EGFR-Presenting Cells with High Density
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
AU2014286872B2 (en) * 2013-07-05 2020-01-23 Formation Biologics Inc. EGFR antibody conjugates
WO2015035410A1 (en) * 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
EP3068892A4 (en) 2013-11-13 2017-05-31 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
MX363543B (en) * 2014-02-04 2019-03-27 Astellas Pharma Inc Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient.
RU2020124944A (en) * 2014-03-21 2020-08-27 Эббви Инк. ANTIBODIES AGAINST EGFR AND ANTIBODY-DRUG CONJUGATES
CA2958882A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
EP3223857A4 (en) * 2014-10-31 2018-06-27 Formation Biologics Inc. Egfr antibody-based combination therapy
KR101692044B1 (en) * 2014-12-05 2017-01-04 사회복지법인 삼성생명공익재단 Method for Predicting Treatment Effects of EGFR Inhibitor in Glioblastoma
WO2016191471A1 (en) * 2015-05-27 2016-12-01 Metastat, Inc. Method of use for inhibitors of epidermal growth factor receptor variants ii, iii and vi
US10426842B2 (en) 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
KR20190138305A (en) * 2017-03-31 2019-12-12 더 큐레이터스 오브 더 유니버시티 오브 미주리 Drug-resistant tumor treatment compositions and methods of using the same
CN107496933B (en) * 2017-08-21 2019-12-24 山东新华制药股份有限公司 Antibody drug conjugate for treating pancreatic cancer and preparation method thereof
KR20230106506A (en) * 2022-01-03 2023-07-13 한국생명공학연구원 Composition for treating non-small cell lung cancer resistant to ALK inhibitors comprising cytidine deaminase inhibitor

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE247168T1 (en) 1991-03-06 2003-08-15 Merck Patent Gmbh HUMANIZED MONOCLONAL ANTIBODIES
RU2139351C1 (en) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся H- and l-chains of monoclonal antibody pm-1 (monat) to human il-6r receptor and their v-region, modified monat, its h- and l-chains and their v-regions, cdr-sequence, dna-sequence
ES2149768T3 (en) 1992-03-25 2000-11-16 Immunogen Inc CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065.
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
PT659439E (en) 1993-12-24 2002-04-29 Merck Patent Gmbh IMUNOCONJUGADOS
HU221001B1 (en) 1994-03-17 2002-07-29 Merck Patent Gmbh. Anti-egfr single-chain fvs, anti-egfr antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999022008A1 (en) 1997-10-27 1999-05-06 Sumitomo Electric Industries, Ltd. Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
ATE419354T1 (en) * 2000-02-25 2009-01-15 Us Gov Health & Human Serv SCFV MOLECULES AGAINST EGFRVIII WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREOF, AND METHODS OF USE THEREOF
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1361893B1 (en) 2001-02-19 2012-10-24 Merck Patent GmbH Modified anti-egfr antibodies with reduced immunogenicity
DE60234094D1 (en) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd SPECIFIC TIE PROTEINS AND ITS USE
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
HUP0600225A3 (en) 2001-06-13 2010-01-28 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
GB0122914D0 (en) 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
WO2004094595A2 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. MODIFIED iRNA AGENTS
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR101531400B1 (en) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
CN1930187B (en) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 For antibody and the use thereof of the deletion mutant of EGF-R ELISA
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ATE501173T1 (en) 2003-12-04 2011-03-15 Abbott Biotherapeutics Corp ANTI-IP-10 ANTIBODIES
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc Methods of generating variant proteins with increased host string content and compositions thereof
WO2005061545A2 (en) 2003-12-22 2005-07-07 Glaxo Group Limited Nogoa antibodies for the treatment of alzheimer disease
AU2005224267B2 (en) 2004-03-19 2011-07-21 Imclone Llc Human anti-epidermal growth factor receptor antibody
SI1733056T1 (en) * 2004-03-31 2013-10-30 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
JP5234734B2 (en) 2004-06-01 2013-07-10 ジェネンテック， インコーポレイテッド Antibody-drug conjugates and methods
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
US20060233814A1 (en) 2005-04-15 2006-10-19 Immunogen Inc. Elimination of heterogeneous or mixed cell population in tumors
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
US7846443B2 (en) 2006-08-11 2010-12-07 Schering Corporation Antibodies to IL-17A
US20090258442A1 (en) 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CN104013956B (en) * 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 Purposes of the anti-egfr antibodies in the mutant mediated disease for the treatment of EGFR
WO2008098145A1 (en) 2007-02-07 2008-08-14 University Of Washington Methods for modulating antigen-specific b cell responses
KR101676622B1 (en) 2007-03-01 2016-11-17 심포젠 에이/에스 Recombinant anti-epidermal growth factor receptor antibody compositions
US7892777B2 (en) 2007-07-17 2011-02-22 The Regents Of The University Of Michigan Methods for measuring whether a treatment affects RPTP-κ activity
WO2009030239A1 (en) 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
US20090269343A1 (en) * 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
CN102083461B (en) 2008-04-30 2014-09-17 伊缪诺金公司 Potent conjugates and hydrophilic linkers
KR101764081B1 (en) 2008-04-30 2017-08-01 이뮤노젠 아이엔씨 Cross-linkers and their uses
SG192517A1 (en) 2008-07-15 2013-08-30 Genentech Inc Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
MX2011001927A (en) 2008-08-29 2011-04-21 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions.
US20110217302A1 (en) 2008-10-10 2011-09-08 Emergent Product Development Seattle, Llc TCR Complex Immunotherapeutics
WO2010055950A1 (en) 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
EP2486023A4 (en) * 2009-10-06 2014-05-07 Immunogen Inc Potent conjugates and hydrophilic linkers
CN103003424B (en) 2010-05-18 2015-05-13 株式会社医学生物学研究所 Antibody capable of binding to transforming growth factor alpha and having antiproliferative activity on cancer having Ras gene mutation
BR112013010544A2 (en) 2010-10-29 2016-08-02 Immunogen Inc egfr and immunoconjugate binding molecules thereof
BR112013010569A2 (en) 2010-10-29 2017-07-04 Immunogen Inc non-antagonistic and immunoconjugated egfr binding molecules thereof
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Also Published As

Publication number Publication date
CL2014001282A1 (en) 2014-11-14
US9233171B2 (en) 2016-01-12
HK1201772A1 (en) 2015-09-11
US20130156796A1 (en) 2013-06-20
PH12014501119A1 (en) 2014-08-04
BR112014012155A2 (en) 2017-05-30
WO2013078271A1 (en) 2013-05-30
JP2014533954A (en) 2014-12-18
EP2794010A4 (en) 2015-10-21
AU2012340686A1 (en) 2014-06-19
RU2014121820A (en) 2015-12-27
IL232666A0 (en) 2014-07-31
CA2856411A1 (en) 2013-05-30
CN104066481A (en) 2014-09-24
MX2014006087A (en) 2014-08-01
KR20140105765A (en) 2014-09-02
EP2794010A1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
HK1201772A1 (en) Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate egfr egfr
IL281714A (en) Methods for increasing efficacy of folr1 cancer therapy
IL228738A0 (en) Antibodies for treatment of cancer
IL228741A0 (en) Method for egfr directed combination treatment of cancer
HK1203091A1 (en) Methods for diagnosis of lung cancer
HK1254859A1 (en) Methods for the treatment of breast cancer
EP2760452A4 (en) Methods of treating cancer
IL232530B (en) Combination of agents for treatment of cancer
EP2885002A4 (en) T-cell redirecting bispecific antibodies for treatment of disease
EP2752198A4 (en) Vaccine preparation for cancer treatment
HK1202240A1 (en) Methods of treating cancer
EP2788378A4 (en) Combination therapy for treatment of cancer
EP2700652A4 (en) Diagnosis and treatment of cancer using anti-itm2a antibody
HK1199261A1 (en) Methods for treatment of diseases
PL2550296T3 (en) Monoclonal antibodies for treatment of cancer
EP2670435A4 (en) Use of anti-dkk1 monoclonal antibody for treatment of liver cancer
HK1207870A1 (en) Anti-human sema4a antibodies useful to treat disease sema4a
IL230479A0 (en) Method for treating cancer by combined use of drugs
EP2849786A4 (en) Methods for treatment of gastric cancer
HK1213584A1 (en) Jam-c antibodies and methods for treatment of cancer jam-c
IL237229A0 (en) Methods for treatment of cancer using lipoplatin
EP2797628A4 (en) Methods for treatment of breast cancer nonresponsive to trastuzumab
EP2755679A4 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
IL232266A0 (en) Methods of treating cancer